Skip to content

US · LIMN · BIOTECHNOLOGY

Liminatus Pharma, Inc. Class A Common Stock (LIMN) intrinsic value and stock valuation

$2.51as of 2026-11-21 · Mkt cap 2.76M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Liminatus Pharma, Inc. Class A Common Stock DCF and intrinsic value

InvestorsCraft values LIMN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LIMN’s statements →

Liminatus Pharma, Inc. Class A Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cerritos, CA 90703 liminatuspharma.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-10.21M
20212025
Free cash flow
-$-9.98M
20212025
Total equity
-$-9.81M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-2.97M-$-2.91M-$-2.59M-$-2.71M-$-2.53M
Net income-$-10.21M-$-2.9M-$-1.23M-$-2.93M$4.37M
EPSd-$-429.89K-$-403.34K-$-153.56K-$-85.1K$126.7K
Operating cash flow-$-9.96M-$-3.11M-$-3.35M-$-870K-$-1.22M
Capital expenditure-$-10K$0.00$0.00$0.00$0.00
Free cash flow-$-9.98M-$-3.11M-$-3.35M-$-870K-$-1.22M
Total assets$510K$2.83M$4.5M$15.5M$276.4M
Total debt$1.44M$5.12M$16.1M$16.5M$90K
Net debt$1.1M$4.32M$15.6M$11.5M-$-250K
Total equity-$-9.81M-$-15.87M-$-10.69M$1.29M$254.9M
Cash and short-term investments$340K$800K$430K$5.05M$340K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$0.00$2.69M$3.76M$1.85M$3.8M
Selling, general and administrative expenses$2.97M$650K$1.06M$860K$200K
Other expenses$0.00-$-420K-$-2.23M$0.00-$-1.46M
Operating expenses$2.97M$2.91M$2.59M$2.71M$2.53M
Cost and expenses$2.97M$2.91M$2.59M$2.71M$2.53M
Interest income$80K$140K$10K$0.00$20K
Interest expense$220K$140K$170K$220K$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-9.99M-$-2.75M-$-1.09M-$-2.71M$4.37M
Operating income-$-2.97M-$-2.91M-$-2.59M-$-2.71M-$-2.53M
Total other income/expenses, net-$-7.24M$20K$1.39M-$-220K$6.9M
Income before tax-$-10.21M-$-2.89M-$-1.19M-$-2.93M$4.37M
Income tax expense$0.00$20K$30K$0.00$0.00
Net income-$-10.21M-$-2.9M-$-1.23M-$-2.93M$4.37M
Weighted average shares outstanding$23.8M$7.19M$8.01M$34.4M$34.5M
Weighted average diluted shares outstanding$23.8M$7.19M$8.01M$34.4M$34.5M
Balance sheet
20252024202320222021
Cash and short-term investments$340K$800K$430K$5.05M$340K
Net receivables$0.00$10K$940K$100K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$500K$810K$210K$360K$420K
Property, plant and equipment, net$10K$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$2.02M$4.29M$15.1M$276M
Total non-current assets$10K$2.02M$4.29M$15.1M$276M
Total assets$510K$2.83M$4.5M$15.5M$276.4M
Accounts payable$580K$1.48M$930K$510K$420K
Short-term debt$1.44M$5.12M$16.1M$16.5M$90K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.3M$8.68M$5.16M$3.59M$1.38M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$30K$10M$10M$10.6M$20.2M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$10.3M$18.7M$15.2M$14.2M$21.6M
Common stock$0.00$1.76M$4.05M$15.1M$276M
Retained earnings-$-38.87M-$-17.52M-$-14.88M-$-13.97M-$-21.13M
Accumulated other comprehensive income (loss)$0.00-$-160K$0.00$0.00$0.00
Total equity-$-9.81M-$-15.87M-$-10.69M$1.29M$254.9M
Total investments$0.00$2.02M$4.29M$15.1M$276M
Total debt$1.44M$5.12M$16.1M$16.5M$90K
Net debt$1.1M$4.32M$15.6M$11.5M-$-250K
Cash flow statement
20252024202320222021
Net income-$-10.21M-$-2.9M-$-4.98M-$-2.93M$4.37M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-6.98M-$-40K$1.64M$1.16M$1.32M
Accounts receivable-$-3.43M$50K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-4.04M$0.00$420K$90K$0.00
Net cash provided by operating activities-$-9.96M-$-3.11M-$-3.35M-$-870K-$-1.22M
Investments in property, plant and equipment-$-10K$0.00$0.00$0.00$0.00
Acquisitions, net$4.44M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-790K$1.97M-$-820K$0.00-$-276M
Common stock issued$10.6M$0.00$0.00$4.2M$283.1M
Common stock repurchased$0.00-$-1.8M-$-10.66M-$-700K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11M$1.05M-$-450K$5.92M$277.6M
Net change in cash$280K$650K-$-4.61M$5.05M$340K
Cash at end of period$340K$800K$430K$5.38M$340K
Operating cash flow-$-9.96M-$-3.11M-$-3.35M-$-870K-$-1.22M
Capital expenditure-$-10K$0.00$0.00$0.00$0.00
Free cash flow-$-9.98M-$-3.11M-$-3.35M-$-870K-$-1.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Liminatus Pharma, Inc. Class A Common Stock

        Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

        CEO
        Chris Kim
        Employees
        1
        Beta
        0.74

        Explore

        Frequently asked questions

        What is the intrinsic value of Liminatus Pharma, Inc. Class A Common Stock (LIMN)?

        InvestorsCraft does not currently publish an intrinsic value for LIMN. How the IC value is calculated.

        Is LIMN undervalued?

        InvestorsCraft does not publish an undervaluation signal for LIMN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.